Roven adenocarcinoma of the stomach that U palliative chemotherapy had again. No phase III trial have been identified. A total of 696 patients with locally advanced gastric cancer and / or metastatic GSK1292263 GPR inhibitor were evaluated for response and toxicity Tons of second-line chemotherapy according to WHO or RECIST criteria. No tests in patients with adenocarcinoma of the feeder Hre. The taxanes, irinotecan, 5-FU oral agents such as capecitabine or S 1, platinum compounds, epirubicin and mitomycin C as second-line treatment tested. Be used in spite of paclitaxel, docetaxel, irinotecan, and S 1 as a single agent, most studies examined the combination therapy. Taxanes are commonly used in a second-line treatment combination of irinotecan, platinum derivatives, agents and 5-FU Including Lich capecitabine and S 1 followed used.
Taxanes Taxanes bind and stabilize microtubules, which were in cell cycle arrest, and these Fingolimod 162359-56-0 agents are used in the front for AGC. Of nine studies that the R Of taxanes in the second-line chemotherapy, paclitaxel 4 and 5 survey examined docetaxel reported. Paclitaxel was used as monotherapy or in combination with a platinum agent. Paclitaxel alone was used in divided doses for patients with poor PS. Weekly paclitaxel was used at 70 mg/m2 in heavily pretreated patients. The efficacy as second-line chemotherapy has been shown by a 4% RR and 5.1 months OS. Leukopenia grade 3 or 4 was found in 23% of patients. Chang et al. reported the efficacy and safety of paclitaxel 200 mg/m2 plus carboplatin AUC 6 in patients previously treated with FP MCO.
The RR of this system was 22% with a median PFS of 14 weeks and without a median overall survival of 32 weeks. However, grade 3 or 4 neutropenia in 40% of patients developed, and a dose adjustment was proposed. The h Most frequent non-h Dermatological toxicity t was neuropathy and joint pain. Combinations of paclitaxel and cisplatin were also investigated. Lee et al. 145 mg/m2 of paclitaxel 60 mg/m2 cisplatin pretreated patients used with FP hospitalized. The RR in this study was 28% with a median overall survival of 9.1 months. Neutropenia of grade 3 or h To her in 9% of patients. A Ern Currency, the h Dose of 175 mg/m2 paclitaxel here by cisplatin 70 mg/m2 every 3 weeks had an RR of 10% and a median survival time of 7.5 months in previously treated patients with AGC-5-FU.
The h Most frequent complication was neutropenia, with grade 3 or 4 was observed in 26% of neutropenic patients. Docetaxel has been used for the AGC as monotherapy or in combination with various other medications. Docetaxel 75 mg/m2 every 3 weeks produced an overall RR of 16% and a median overall survival of 8.3 months for patients who do not have the first-line treatment with PF, 18% of patients developed grade 3 or 4 neutropenia. The percentage of patients with non-dermatological toxicity t h grade 3 orworse were: asthenia, diarrhea and peripheral sensory neuropathy. Kim et al. given docetaxel 75 mg/m2 and cisplatin 60 mg/m2 every 3 weeks and found that 32% theRRwas amedianOSof at 7.8 months. The h Most frequent toxicity t grade 3 or 4 of this plan was neutropenia, 51%, followed by leukopenia and followed oral mucositis. In another Hnlichen study by Park et al, docetaxel 60 mg/m2 and cisplatin 60 mg/m2 every 3 weeks in patients who do not have an AGC System 5-FU